Neuroendocrine Cancer: Radiotherapy
The question
To ask the Secretary of State for Health and Social Care, when he plans to update NHS commissioning policy to include funding for Selective Internal Radiation Therapy for patients with neuroendocrine tumours with liver metastases.
Answered by Ashley Dalton
The Department recognises the need to offer patients the most suitable treatment, including the use of selective internal radiation therapy (SIRT).
NHS England is currently in the early stages of policy development for SIRT as an additional treatment option for patients with neuroendocrine tumours with liver metastases. NHS England, through its specialised commissioning function, is responsible for setting national service standards, and for the development of clinical commissioning policies for prescribed specialised services. Should NHS England’s Clinical Panel consider that the evidence is robust enough to warrant making the treatment routinely available across the National Health Service in England, it will require further consideration through relative prioritisation and investment.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →